SDGR vs. SUPN, ZLAB, HRMY, AVDL, CPRX, EVO, KURA, TARO, GPCR, and AGIO
Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Supernus Pharmaceuticals (SUPN), Zai Lab (ZLAB), Harmony Biosciences (HRMY), Avadel Pharmaceuticals (AVDL), Catalyst Pharmaceuticals (CPRX), Evotec (EVO), Kura Oncology (KURA), Taro Pharmaceutical Industries (TARO), Structure Therapeutics (GPCR), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Schrödinger (NASDAQ:SDGR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
Schrödinger presently has a consensus price target of $42.80, indicating a potential upside of 88.30%. Supernus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 41.57%. Given Schrödinger's higher probable upside, equities research analysts clearly believe Schrödinger is more favorable than Supernus Pharmaceuticals.
Schrödinger has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.
Schrödinger has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
In the previous week, Supernus Pharmaceuticals had 10 more articles in the media than Schrödinger. MarketBeat recorded 13 mentions for Supernus Pharmaceuticals and 3 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.63 beat Supernus Pharmaceuticals' score of 0.43 indicating that Schrödinger is being referred to more favorably in the media.
79.1% of Schrödinger shares are held by institutional investors. 7.6% of Schrödinger shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Supernus Pharmaceuticals has a net margin of -2.60% compared to Schrödinger's net margin of -75.94%. Supernus Pharmaceuticals' return on equity of -1.68% beat Schrödinger's return on equity.
Supernus Pharmaceuticals received 423 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
Summary
Supernus Pharmaceuticals beats Schrödinger on 10 of the 18 factors compared between the two stocks.
Get Schrödinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrödinger Competitors List
Related Companies and Tools
